Idebenone as a novel therapeutic approach for duchenne muscular dystrophy

Gunnar M. Buyse, Nuri Gueven, Craig M McDonald

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Progressive loss of pulmonary function leads to early morbidity and mortality in Duchenne muscular dystrophy (DMD) due to both expiratory impairment with ineffective airway clearance, and inspiratory impairment leading to nocturnal and daytime hypoventilation and respiratory failure. Glucocorticoid steroids have become a mainstay of DMD therapy with well-documented efficacy on muscle strength and respiratory function. However, the side-effect profile restricts their long-term use, particularly in non-ambulant patients. Idebenone improves secondary mitochondrial dysfunction caused by dystrophin deficiency, intracellular calcium accumulation and increased reactive oxygen species (ROS). Idebenone-mediated improved bioenergetics leads to enhanced adenosine triphosphate (ATP) production and reduced ROS. Based on this rationale, idebenone has been investigated clinically for efficacy on reducing respiratory function decline in exploratory phase II (DELPHI) and confirmatory phase III (DELOS) trials. Idebenone significantly reduced the loss of respiratory function in 8–18-year-old DMD patients who were not using concomitant glucocorticoids. These results indicate that idebenone can modify the natural course of respiratory disease progression in DMD, which is relevant in clinical practice where loss of respiratory function continues to be a predominant cause of early morbidity and mortality in DMD.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalEuropean Neurological Review
Volume10
Issue number2
StatePublished - 2015

Fingerprint

Duchenne Muscular Dystrophy
Glucocorticoids
Reactive Oxygen Species
Morbidity
Therapeutics
Hypoventilation
Dystrophin
Mortality
Muscle Strength
Respiratory Insufficiency
Energy Metabolism
Disease Progression
Adenosine Triphosphate
Steroids
idebenone
Calcium
Lung

Keywords

  • Duchenne muscular dystrophy
  • Glucocorticoid steroid
  • Idebenone
  • Peak expiratory flow
  • Respiratory function

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Idebenone as a novel therapeutic approach for duchenne muscular dystrophy. / Buyse, Gunnar M.; Gueven, Nuri; McDonald, Craig M.

In: European Neurological Review, Vol. 10, No. 2, 2015, p. 189-194.

Research output: Contribution to journalArticle

@article{a8ce76bf14414749a6645bebef31b2db,
title = "Idebenone as a novel therapeutic approach for duchenne muscular dystrophy",
abstract = "Progressive loss of pulmonary function leads to early morbidity and mortality in Duchenne muscular dystrophy (DMD) due to both expiratory impairment with ineffective airway clearance, and inspiratory impairment leading to nocturnal and daytime hypoventilation and respiratory failure. Glucocorticoid steroids have become a mainstay of DMD therapy with well-documented efficacy on muscle strength and respiratory function. However, the side-effect profile restricts their long-term use, particularly in non-ambulant patients. Idebenone improves secondary mitochondrial dysfunction caused by dystrophin deficiency, intracellular calcium accumulation and increased reactive oxygen species (ROS). Idebenone-mediated improved bioenergetics leads to enhanced adenosine triphosphate (ATP) production and reduced ROS. Based on this rationale, idebenone has been investigated clinically for efficacy on reducing respiratory function decline in exploratory phase II (DELPHI) and confirmatory phase III (DELOS) trials. Idebenone significantly reduced the loss of respiratory function in 8–18-year-old DMD patients who were not using concomitant glucocorticoids. These results indicate that idebenone can modify the natural course of respiratory disease progression in DMD, which is relevant in clinical practice where loss of respiratory function continues to be a predominant cause of early morbidity and mortality in DMD.",
keywords = "Duchenne muscular dystrophy, Glucocorticoid steroid, Idebenone, Peak expiratory flow, Respiratory function",
author = "Buyse, {Gunnar M.} and Nuri Gueven and McDonald, {Craig M}",
year = "2015",
language = "English (US)",
volume = "10",
pages = "189--194",
journal = "European Neurological Review",
issn = "1758-3837",
publisher = "Touch Briefings",
number = "2",

}

TY - JOUR

T1 - Idebenone as a novel therapeutic approach for duchenne muscular dystrophy

AU - Buyse, Gunnar M.

AU - Gueven, Nuri

AU - McDonald, Craig M

PY - 2015

Y1 - 2015

N2 - Progressive loss of pulmonary function leads to early morbidity and mortality in Duchenne muscular dystrophy (DMD) due to both expiratory impairment with ineffective airway clearance, and inspiratory impairment leading to nocturnal and daytime hypoventilation and respiratory failure. Glucocorticoid steroids have become a mainstay of DMD therapy with well-documented efficacy on muscle strength and respiratory function. However, the side-effect profile restricts their long-term use, particularly in non-ambulant patients. Idebenone improves secondary mitochondrial dysfunction caused by dystrophin deficiency, intracellular calcium accumulation and increased reactive oxygen species (ROS). Idebenone-mediated improved bioenergetics leads to enhanced adenosine triphosphate (ATP) production and reduced ROS. Based on this rationale, idebenone has been investigated clinically for efficacy on reducing respiratory function decline in exploratory phase II (DELPHI) and confirmatory phase III (DELOS) trials. Idebenone significantly reduced the loss of respiratory function in 8–18-year-old DMD patients who were not using concomitant glucocorticoids. These results indicate that idebenone can modify the natural course of respiratory disease progression in DMD, which is relevant in clinical practice where loss of respiratory function continues to be a predominant cause of early morbidity and mortality in DMD.

AB - Progressive loss of pulmonary function leads to early morbidity and mortality in Duchenne muscular dystrophy (DMD) due to both expiratory impairment with ineffective airway clearance, and inspiratory impairment leading to nocturnal and daytime hypoventilation and respiratory failure. Glucocorticoid steroids have become a mainstay of DMD therapy with well-documented efficacy on muscle strength and respiratory function. However, the side-effect profile restricts their long-term use, particularly in non-ambulant patients. Idebenone improves secondary mitochondrial dysfunction caused by dystrophin deficiency, intracellular calcium accumulation and increased reactive oxygen species (ROS). Idebenone-mediated improved bioenergetics leads to enhanced adenosine triphosphate (ATP) production and reduced ROS. Based on this rationale, idebenone has been investigated clinically for efficacy on reducing respiratory function decline in exploratory phase II (DELPHI) and confirmatory phase III (DELOS) trials. Idebenone significantly reduced the loss of respiratory function in 8–18-year-old DMD patients who were not using concomitant glucocorticoids. These results indicate that idebenone can modify the natural course of respiratory disease progression in DMD, which is relevant in clinical practice where loss of respiratory function continues to be a predominant cause of early morbidity and mortality in DMD.

KW - Duchenne muscular dystrophy

KW - Glucocorticoid steroid

KW - Idebenone

KW - Peak expiratory flow

KW - Respiratory function

UR - http://www.scopus.com/inward/record.url?scp=84952655668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952655668&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84952655668

VL - 10

SP - 189

EP - 194

JO - European Neurological Review

JF - European Neurological Review

SN - 1758-3837

IS - 2

ER -